Skip to main navigation
Logo

Live - Corprorate Menu

  • About Us
    • Our Leadership
    • Diversity, Equity, and Inclusion
    • Collaborations
    • Compliance and Ethics
    • Corporate Giving
  • Our Focus
    • Cerebral Adrenoleukodystrophy
    • Sickle Cell Disease
    • Transfusion Dependant Beta-Thalassemia
  • Our Science
    • Our Approach to Gene Therapy
    • Our Treatment Process
    • Our Pipeline
    • Clinical Trials
  • Our Therapies
  • Patients & Advocacy
    • Patient Advocacy
    • Patient Resources
    • Access Policy

Live - Top Nav

  • investors & media
  • contact us
  • careers

Investors & Media

Overview Corporate Governance Press Releases Events & Presentations Analyst Coverage Stock Information SEC Filings Investor FAQs

Toolkit

  • Annual Meeting
  • Information Request
  • Sign Up for Email Alerts
  • RSS Feeds

Media Contacts

  • Jess Rowlands

    Head of Corporate Communications

    (857) 299-6103

    jess.rowlands@bluebirdbio.com

Investor Contacts

  • Courtney O’Leary

    Investor Relations

    (978) 621-7347

    coleary@bluebirdbio.com

bluebird bio Reports First Quarter 2023 Financial Results and Highlights Operational Progress

  • Read more about bluebird bio Reports First Quarter 2023 Financial Results and Highlights Operational Progress

Eric Joseph

    Eric Joseph
    J.P. Morgan

    BofA Securities 2023 Health Care Conference

    • Read more about BofA Securities 2023 Health Care Conference

    bluebird bio Announces First Quarter 2023 Earnings Date and Upcoming Investor Events

    • Read more about bluebird bio Announces First Quarter 2023 Earnings Date and Upcoming Investor Events

    bluebird bio Submits Biologics License Application (BLA) to FDA for lovotibeglogene autotemcel (lovo-cel) for Patients with Sickle Cell Disease (SCD) 12 years and Older with a History of Vaso-Occlusive Events

    • Read more about bluebird bio Submits Biologics License Application (BLA) to FDA for lovotibeglogene autotemcel (lovo-cel) for Patients with Sickle Cell Disease (SCD) 12 years and Older with a History of Vaso-Occlusive Events

    bluebird bio Reports Fourth Quarter and Full Year 2022 Financial Results and Highlights Operational Progress

    • Read more about bluebird bio Reports Fourth Quarter and Full Year 2022 Financial Results and Highlights Operational Progress

    bluebird bio 4th Quarter & Full Year 2022 Earnings Call

    • Read more about bluebird bio 4th Quarter & Full Year 2022 Earnings Call

    Jack Allen

      Jack Allen
      Baird

      bluebird bio, Inc. Announces Pricing of $120 Million Public Offering of Common Stock

      • Read more about bluebird bio, Inc. Announces Pricing of $120 Million Public Offering of Common Stock

      bluebird bio, Inc. Announces Proposed Public Offering of Common Stock

      • Read more about bluebird bio, Inc. Announces Proposed Public Offering of Common Stock

      Pagination

      • Current page 1
      • Page 2
      • Page 3
      • Page 4
      • Page 5
      • Page 6
      • Page 7
      • Page 8
      • Page 9
      • …
      • Next page Next ›
      • Last page Last »
      Subscribe to

      Quick Links

      • Patients & Advocacy
      • Investors & Media
      • Careers
      • Contact Us

      CONTACT INFO

      info@bluebirdbio.com

      clinicaltrials@bluebirdbio.com

      investor@bluebirdbio.com

      medinfo@bluebirdbio.com

      Live - Terms & Privacy

      • Terms of Service
      • Privacy Policy
      • Cookie Notice
      • Sitemap
      © 2023 bluebird bio, Inc. All Rights Reserved. Corp-US-00175 04/22

      Live - Social Links